Dateline City:
KENILWORTH, N.J.
First Presentation of Data from Phase 3 KEYNOTE-045 Study Presented at the Society for Immunotherapy of Cancers (SITC) 31 st Annual Meeting
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced results from the pivotal KEYNOTE-045 study investigating
the use of KEYTRUDA (pembrolizumab), the companys anti-PD-1
therapy, in patients with advanced bladder (urothelial) cancer
previously treated with platinum-containing chemotherapy. As previously
announced, KEYTRUDA was superior to investigator-choice chemotherapy for
the primary endpoint of overall survival (OS) in this phase 3 study, and
was stopped early.
Language:
English
Contact:
MerckMedia:Pamela Eisele, 267-305-3558orCourtney Ronaldo, 908-236-1108orInvestors:Teri Loxam, 908-740-1986orAmy Klug, 908-740-1898
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more